/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer
S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air · Oct 14, 2026

Next-gen ADCs, cell-cycle targets, and tailored regimens are revolutionizing care paradigms across diverse ovarian cancer subtypes.

Switching ADC Payloads Preserves Antitumor Activity When Overcoming Target Cross-Resistance

Dr. Liu highlights that sequentially administering ADCs remains active if clinicians change the cytotoxic payload, even when targeting the identical receptor. Conversely, emerging prospective breast cancer trials indicate that sequencing a topoisomerase I inhibitor ADC directly after another yields very low antitumor response rates.

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer thumbnail

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air·a month ago

Emerging Ovarian ADCs Eliminate Strict High-Biomarker Cutoffs Required by First-Generation Agents

Next-generation topoisomerase I payload ADCs are showing up to 50% response rates in platinum-resistant ovarian cancer without requiring high biomarker expression. Unlike mirvetuximab or trastuzumab deruxtecan, these emerging agents could broaden clinical accessibility to broader patient populations without upfront IHC biomarker stratification.

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer thumbnail

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air·a month ago

Dual-Payload ADCs Function Like Targeted Combination Chemotherapy to Circumvent Monotherapy Resistance

Next-generation dual-payload ADCs combine distinct mechanisms, such as microtubule inhibitors with topoisomerase I inhibitors or ATR inhibitors, effectively acting as targeted combination chemotherapy. Dr. Liu notes their success will depend heavily on whether efficacy outweighs toxicities caused by free payloads circulating systemically.

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer thumbnail

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air·a month ago

Cyclin E1 Protein Overexpression Creates Vulnerability to G2M Checkpoint Inhibitors

Tumors can overexpress Cyclin E1 protein without genomic CCNE1 amplification, driving chronic G1/S progression and replication stress. This leaves malignant cells strictly dependent on the G2/M checkpoint for survival, where WEE1 inhibitors like azenosertib demonstrate promising 30% to 35% response rates in clinical evaluation.

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer thumbnail

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air·a month ago

Chromosomal Instability Drives High-Grade Serous Ovarian Cancer Reliance on KIF18A Centering

High-grade serous ovarian cancer exhibits high chromosomal instability, leaving cells vulnerable when mitotic chromosome alignment fails. Inhibiting KIF18A, a kinesin motor that centers chromosomes on the metaphase plate, prevents even segregation and forces tumor cells into mitotic catastrophe and subsequent cell death.

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer thumbnail

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air·a month ago

Defactinib Blocks FAK-Mediated Resistance in Avutametnib-Treated KRAS-Mutated Low-Grade Serous Cancer

In KRAS-mutant low-grade serous ovarian cancer, blocking RAS-RAF-MEK signaling triggers compensatory FAK pathway upregulation as an escape mechanism. Combining the RAF/MEK clamp avutametnib with FAK inhibitor defactinib abrogates this bypass resistance, demonstrating notable activity that recently secured accelerated FDA approval.

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer thumbnail

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

OncLive® On Air·a month ago